Fall from Grace: How Covid-19 Vaccine Manufacturers Adapt to Lower Demand in Switzerland

During the peak of the Covid-19 pandemic, vaccine manufacturers earned billions in revenue. However, as demand for vaccines has dropped in Switzerland, companies have experienced significant financial losses. Biontech and Moderna, two leading vaccine manufacturers, have fallen into the red due to a drop in sales. AstraZeneca stopped manufacturing and marketing their product due to lack of demand.

Novavax, a biotech company that produces protein-based Covid vaccines, entered the market late but received a financial injection from Sanofi to continue research and development. The collaboration aims to boost sales of the Covid vaccine and develop a combined flu and Covid vaccine in the future to stimulate demand. Like Biontech and Moderna, Sanofi hopes to maintain revenue streams through alternative strategies.

Despite significant financial losses, these companies continue to invest in research and development to stay competitive in a changing landscape of the vaccine industry in a post-pandemic world.